Ariad Pharm misses by $0.06, misses on revs; updates 2015 guidance
- Reports Q2 (Jun) loss of $0.33 per share, $0.06 worse than the Capital IQ Consensus Estimate of ($0.27); total revenues rose 141.3% year/year to $29.2 mln vs the $31.89 mln consensus.
- Net product revenues from Iclusig were $27.8 mln, an increase of 134% vs 2Q14 and 16% vs 1Q15. Q2 Iclusig product revenues are comprised of revenues of $21.6 million in the U.S. and $6.2 million in Europe.
- Co expects Iclusig revenues for 2015 to be in the range of $130-140 million.
- Co expects its cash & cash equivalents at December 31, 2015 to be at least $240 million.